| bimatoprost / Generic mfg. |
NCT00487214: Internet-based, Naturalistic Evaluation of Tolerability and Individual Patient Target Pressures With Bimatoprost 0.03% in Glaucoma |
|
|
| Completed | N/A | 361 | US | | Allergan | Glaucoma, Open-Angle | 02/03 | 02/03 | | |
NCT00187577: Efficacy Study of Latanoprost and Bimatoprost Solutions in Promoting Eyelash Growth in Patients With Alopecia Areata |
|
|
| Completed | N/A | 14 | US | Latanoprost (Xalatan), Bimatoprost (Lumigan), Bimatoprost 0.03% solution (Lumigan), Topical application of latanoprost solution to eyelid | University of California, San Francisco | Alopecia Areata | 02/06 | 03/06 | | |
NCT00716742: Safety and Efficacy Study of Bimatoprost, Latanoprost, and Travoprost in Patients With Elevated Intraocular Pressure (IOP) and Open-angle Glaucoma (OAG) |
|
|
| Completed | N/A | 1099 | US | bimatoprost 0.03%, latanoprost 0.005%, and travoprost 0.004%, Lumigan®, Xalatan®, Travatan® | Allergan | Open-Angle Glaucoma, Ocular Hypertension | 09/07 | 09/09 | | |
NCT00567788: Comparison of Bimatoprost and Latanoprost in Patients With Chronic Angle-Closure Glaucoma: A Randomized Cross-Over Study |
|
|
| Unknown status | N/A | 60 | RoW | Latanoprost-Bimatoprost, Xalatan, Lumigan, Bimatoporost-Latanoprost | Singapore National Eye Centre, Allergan | Glaucoma, Angle-Closure | | 07/08 | | |
NCT00773136: Eyelash Growth From Application of Bimatoprost in Gel Suspension to the Base of the Eyelashes |
|
|
| Completed | N/A | 21 | US | Bimatoprost Suspension, Lumigan | University of Miami | Hypertrichosis | 07/08 | 07/08 | | |
NCT01092273: Bimatoprost Versus Travoprost at Cairo University |
|
|
| Completed | N/A | | RoW | | Cairo University | Glaucoma, Ocular Hypertension | | | | |
NCT01632423: A Study of Lumigan® in Patients With Primary Open Angle Glaucoma (POAG) or Ocular Hypertension (OHT) |
|
|
| Completed | N/A | 10337 | Europe | bimatoprost 0.01% | Allergan | Glaucoma, Open-Angle, Ocular Hypertension | 11/10 | 11/10 | | |
NCT01628588: Lumigan® in Patients With Primary Open Angle Glaucoma (POAG) or Ocular Hypertension (OHT) |
|
|
| Completed | N/A | 854 | Europe | bimatoprost 0.01% | Allergan | Glaucoma, Open-Angle, Ocular Hypertension | 12/10 | 12/10 | | |
NCT01628601: GANfort® in Patients With Primary Open Angle Glaucoma or Ocular Hypertension Who Are Insufficiently Responsive to Monotherapy |
|
|
| Completed | N/A | 392 | Europe | Fixed combination 0.3 mg bimatoprost and 5 mg timolol | Allergan | Glaucoma, Open-Angle, Ocular Hypertension | 06/11 | 06/11 | | |
NCT01623479: An Observational Study of Patients Treated With Bimatoprost 0.03% (Latisse®) for Hypotrichosis of the Eyelashes |
|
|
| Completed | N/A | 585 | US | bimatoprost 0.03%, Latisse® | Allergan | Eyelash Hypotrichosis | 09/11 | 09/11 | | |
NCT01361841: Effects of Latanoprost, Bimatoprost and Travoprost in Patients With Latanoprost-resistant Glaucoma |
|
|
| Unknown status | N/A | 141 | Canada | Latanoprost, bimatoprost, travoprost, Xalatan, Lumigan, Travatan, travoprost, latanoprost and bimatoprost | Centre de recherche du Centre hospitalier universitaire de Sherbrooke | Ocular Hypertension, Primary Glaucoma | 01/12 | 01/13 | | |
NCT01568008: Observational Study of Lumigan® 0.01% for Treatment of Primary Open Angle Glaucoma (POAG) or Ocular Hypertension (OHT) |
|
|
| Completed | N/A | 933 | Europe | Bimatoprost 0.01% ophthalmic solution, Lumigan® | Allergan | Open-Angle Glaucoma, Ocular Hypertension | 09/12 | 09/12 | | |
NCT01589510: A Study of Lumigan® 0.01% in Patients With Primary Open Angle Glaucoma (POAG) or Ocular Hypertension (OHT) |
|
|
| Completed | N/A | 419 | Europe | bimatoprost 0.01% ophthalmic solution, Lumigan® 0.01% | Allergan | Glaucoma, Open-Angle, Ocular Hypertension | 02/13 | 02/13 | | |
NCT01489670: Observational Study of Lumigan® 0.01% Treatment for Patients With Primary Open Angle Glaucoma or Ocular Hypertension |
|
|
| Completed | N/A | 387 | Europe | bimatoprost 0.01% ophthalmic solution, Lumigan® 0.01% | Allergan | Glaucoma, Open-Angle, Ocular Hypertension | 03/13 | 03/13 | | |
NCT01646151: A Study Comparing IOP-Lowering Treatments to Bimatoprost in Patients With Primary Open Angle Glaucoma or Ocular Hypertension |
|
|
| Completed | N/A | 2580 | Europe | Bimatoprost, LUMIGAN®, GANFORT® | Allergan | Glaucoma, Open-Angle, Ocular Hypertension | 04/13 | 04/13 | | |
NCT01507584: The Effects of the Water Drinking Test on Intraocular Pressure |
|
|
| Completed | N/A | 23 | US | SENSIMED Triggerfish, bimatoprost (Lumigan); brinzolamide (azopt) | University of California, San Diego | Glaucoma | 04/13 | 04/13 | | |
NCT01853085: A Study of Patients With Primary Open Angle Glaucoma or Ocular Hypertension Switched to Lumigan® UD Monotherapy for Medical Reasons |
|
|
| Completed | N/A | 1830 | Europe | Bimatoprost Ophthalmic Solution, Lumigan® UD | Allergan | Glaucoma, Primary Open Angle, Ocular Hypertension | 03/14 | 03/14 | | |
| Completed | N/A | 312 | RoW | Bimatoprost 0.01%, Lumigan® 0.01% | Allergan | Glaucoma, Primary Open Angle, Ocular Hypertension | 08/14 | 08/14 | | |
NCT02138461: Tolerability of Bimatoprost 0.01% vs Latanoprost Eye Drops |
|
|
| Completed | N/A | 211 | US | | MDbackline, LLC, Allergan | Glaucoma | 09/14 | 09/14 | | |
NCT02448043: Cutaneous Prostaglandin Application: Nail Growth, Nail Brittleness, and Eye Pressure |
|
|
| Completed | N/A | 45 | US | Bimatoprost 0.01%, Lumigan 0.01%, Placebo: saline | Northwestern University, Allergan | Nail Growth Cessation, Intraocular Pressure | 05/16 | 05/16 | | |
NCT00999557: Bimatoprost Ophthalmic Solution in Increasing Eyebrow and Eyelash Growth in Patients Who Have Undergone Chemotherapy for Breast Cancer and in Healthy Participants |
|
|
| Withdrawn | N/A | 0 | US | bimatoprost ophthalmic solution, placebo | Jonsson Comprehensive Cancer Center | Alopecia, Breast Cancer | 08/17 | | | |
NCT02505776: Safety and Patient Satisfaction With GLASH VISTA™ (Bimatoprost 0.03%) in the Treatment of Eyelash Hypotrichosis in Japan |
|
|
| Completed | N/A | 1699 | Japan | Bimatoprost cutaneous solution 0.03%, GLASH VISTA™, Latisse® | Allergan | Eyelash Hypotrichosis | 05/18 | 05/18 | | |
NCT02774811: Primary Glaucoma Treatment Trial in Kenya and South Africa - SLT vs. Medication |
|
|
| Terminated | N/A | 15 | RoW | Prostaglandin analogue, Bimatoprost, Selective laser trabeculoplasy, laser | University College, London, University of KwaZulu, Kisii Eye Hospital Kisii Kenya | Glaucoma | 01/19 | 01/19 | | |
NCT04380025: Mirtogenol and Bimatoprost on IOP in Hispanics With Open-Angle Glaucoma |
|
|
| Unknown status | N/A | 72 | US | Experimental: Oral Mirtogenol, Bilberry with pycnogenol, Placebo of oral Dietary supplement, lactose and food grade dyes | University of Puerto Rico | Glaucoma | 03/21 | 05/21 | | |
NCT04828057: Preservative-free Fixed-dose Combination of Tafluprost 0.0015% / Timolol 0.5% in Patients With Open-angle Glaucoma or Ocular Hypertension: Clinical Effectiveness, Tolerability and Safety in a Real World Setting |
|
|
| Completed | N/A | 50 | RoW | Tafluprost, timolol maleate, latanoprost, tafluprost, bimatoprost, travoprost | Santen Pharmaceutical (Taiwan) Co., LTD | Ocular Surface Disease, Primary Open Angle Glaucoma | 08/22 | 08/22 | | |
NCT06993597: Study of Corneal Biomechanics in Glaucoma Patients Using Brillouin Microscopy |
|
|
| Recruiting | N/A | 60 | US | Prostaglandin Analogue -Containing IOP-Lowering Therapy, Latanoprost, Travaprost, Bimatoprost, Beta Blocker, Timolol, Brillouin Microscopy, Brillouin Imaging | University of Maryland, Baltimore, National Eye Institute (NEI) | Glaucoma | 03/26 | 06/26 | | |
